Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Regorafenib in refractory biliary tract cancer

Richard D. Kim • 3 Jul 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer FOLFOX Regorafenib
ABC-06

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, in refractory biliary tract cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Richard D. Kim

2:15
The role of immunotherapy in cholangiocarcinoma
Richard D. Kim et al. • 26 Jan 2023
2:40
Biomarker analysis of nivolumab in patients with advanced refractory biliary tract cancer
Richard D. Kim et al. • 26 Jan 2023
1:55
The latest in targeted therapies for advanced colorectal cancer
Richard D. Kim et al. • 26 Jan 2023
2:44
Biomarkers of treatment response in patients with MMR-proficient CRC
Richard D. Kim et al. • 26 Jan 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals